PMID- 32547607
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1671-5411 (Print)
IS  - 1671-5411 (Linking)
VI  - 17
IP  - 5
DP  - 2020 May
TI  - Long-term follow-up of antithrombotic management patterns in patients with acute 
      coronary syndrome in China.
PG  - 246-255
LID - 10.11909/j.issn.1671-5411.2020.05.008 [doi]
AB  - OBJECTIVE: To describe the long-term antithrombotic management patterns (AMPs) 
      and clinical outcomes of Chinese patients with acute coronary syndrome (ACS). 
      METHODS: This was an observational, multicenter, longitudinal cohort extension 
      study of Chinese patients who had completed the EPICOR Asia 2-year follow-up 
      study post-hospitalization for an ACS event. Changes in AMP and clinical outcomes 
      for up to 5 years post-ACS event were evaluated. RESULTS: Overall, 2334 patients 
      with ACS were enrolled at 49 sites. The mean age was 61.6 years and 76.3% were 
      men. By study end, 2093 patients completed the 3-year follow-up. At baseline (2 
      years post-ACS event), 72.4% of patents received one antiplatelet (AP) 
      medication, with aspirin being the preferred one. A small proportion of patients 
      (21.5%) was treated with two or more APs (2+ AP), and even fewer patients (6.1%) 
      did not receive any AP medication at baseline. Upon study completion, the 
      proportion of patients without AP therapy increased to 13.6%, while the 
      percentage of patients on one AP and 2+ AP decreased to 69.3% and 17.1%, 
      respectively. Numerically, a higher incidence of clinical events (composite of 
      all-cause mortality, myocardial infarction, stroke) was observed for the 2+ AP 
      (13.2%) subgroup than for the no AP (10.5%) and one AP (8.6%) subgroups. 
      Furthermore, the 2+ AP subgroup exhibited the greatest number of bleeding events, 
      outpatient visits, and hospitalization rates. Unlike myocardial infarction or 
      stroke, bleeding events prompted an adjustment in AMP. CONCLUSION: Most patients 
      in China received at least one AP medication up to 5 years after an ACS event.
CI  - Institute of Geriatric Cardiology.
FAU - Han, Xiao-Ning
AU  - Han XN
AD  - Department of Cardiology, Peking University First Hospital, Beijing, China.
FAU - Qiao, Shu-Bin
AU  - Qiao SB
AD  - National Center for Cardiovascular Diseases, Fuwai Hospital, Beijing, China.
FAU - Ge, Jun-Bo
AU  - Ge JB
AD  - Department of Cardiology, Zhongshan Hospital Affiliated to Fudan University, 
      Guangzhou, China.
FAU - Han, Ya-Ling
AU  - Han YL
AD  - Department of Cardiology, the General Hospital of Shenyang Military, Shenyang, 
      China.
FAU - Chen, Ji-Yan
AU  - Chen JY
AD  - Department of Cardiology, Guangdong General Hospital, Guangzhou, China.
FAU - Yuan, Zu-Yi
AU  - Yuan ZY
AD  - Department of Cardiology, the First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Yu, Bo
AU  - Yu B
AD  - Department of Cardiology, the Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Jiang, Jie
AU  - Jiang J
AD  - Department of Cardiology, Peking University First Hospital, Beijing, China.
FAU - Huo, Yong
AU  - Huo Y
AD  - Department of Cardiology, Peking University First Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Geriatr Cardiol
JT  - Journal of geriatric cardiology : JGC
JID - 101237881
PMC - PMC7276310
OTO - NOTNLM
OT  - Acute coronary syndrome
OT  - Antithrombotic agents
OT  - Antithrombotic management patterns
OT  - Observational study
OT  - Real-world
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
PMCR- 2020/05/01
CRDT- 2020/06/18 06:00
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
AID - jgc-17-05-246 [pii]
AID - 10.11909/j.issn.1671-5411.2020.05.008 [doi]
PST - ppublish
SO  - J Geriatr Cardiol. 2020 May;17(5):246-255. doi: 
      10.11909/j.issn.1671-5411.2020.05.008.